Ask AI
Bill116th CongressFiled Apr 29, 2019Health
S. 1224

Stop STALLING Act

Bill journey · stage 2 of 5

Under committee review

Filed
Comm.
Floor
Both
Law

What it doesSummary reported to senate (Jun 28, 2019)

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

What just happenedJun 28, 2019

Placed on Senate Legislative Calendar under General Orders. Calendar No. 130.

Who’s behind it

Sen. Klobuchar, Amy [D-MN](D-MN)Sponsor
1 cosponsor1 R
Read on Congress.gov
1cosponsors1committees6actions2related bills8subjects
  1. Jun 28, 2019Calendars

    Placed on Senate Legislative Calendar under General Orders. Calendar No. 130.

  2. Jun 28, 2019Committee

    Committee on the Judiciary. Reported by Senator Graham with an amendment in the nature of a substitute and an amendment to the title. Without written report.

    Judiciary Committee
  3. Jun 28, 2019Committee14000

    Committee on the Judiciary. Reported by Senator Graham with an amendment in the nature of a substitute and an amendment to the title. Without written report.

    Judiciary Committee
  4. Jun 27, 2019Committee

    Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.

    Judiciary Committee
  5. Apr 29, 2019IntroReferral

    Read twice and referred to the Committee on the Judiciary.

    Judiciary Committee
  6. Apr 29, 2019IntroReferral10000

    Introduced in Senate

Reported to SenateJun 28, 201925

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Introduced in SenateApr 29, 2019

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Stop STALLING Act — Informed